Last reviewed · How we verify
KL1333
KL1333 is a small molecule that targets the mitochondrial permeability transition pore (mPTP) to induce cell death in cancer cells.
KL1333 is a small molecule that targets the mitochondrial permeability transition pore (mPTP) to induce cell death in cancer cells. Used for Treatment of various types of cancer, including glioblastoma and melanoma.
At a glance
| Generic name | KL1333 |
|---|---|
| Sponsor | Abliva AB |
| Drug class | Mitochondrial permeability transition pore inhibitor |
| Target | mPTP |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting the mPTP, KL1333 triggers a rapid and irreversible cell death in cancer cells, making it a potential therapeutic agent for various types of cancer. This mechanism of action is distinct from traditional chemotherapy and radiation therapy, which often cause damage to both cancer and healthy cells.
Approved indications
- Treatment of various types of cancer, including glioblastoma and melanoma
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease (PHASE2)
- A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease (PHASE1)
- Drug-drug Interaction Study of KL1333 in Healthy Subjects (PHASE1)
- Safety, Tolerability and Pharmacokinetic Study of KL1333 in Healthy Male Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KL1333 CI brief — competitive landscape report
- KL1333 updates RSS · CI watch RSS
- Abliva AB portfolio CI